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and curtail the development of drug resistance. Innovations in
reinforcement of this strategy should further facilitate its deliv-
ery and enhance its effectiveness. However, established MDR-TB
is notoriously difﬁcult to treat, and necessitates the use of alter-
native speciﬁc anti-TB chemotherapy regimens. These regimens
comprise combination use of second-line and third-line anti-TB
drugs, that are generally more costly and toxic, and have to
be given for longer durations – usually in the range of 18–24
months. The ﬂuoroquinolones, better tolerated by patients, have
a pivotal role in MDR-TB treatment. Optimal delivery of these
treatment regimens mandates a programmatic basis which is now
included under the Stop-TB Drug-Resistance Programme(s). The
key components embrace political commitment, quality-assured
drug susceptibility testing, reliable supply of quality drugs, de-
livery of chemotherapy under directly observed settings, and a
sound recording and reporting system to monitor the individual
treatment outcome of patient and overall performance of the
TB control programme. Adjunctive surgery in selected MDR-TB
patients help to improve their treatment success. Further ex-
ploration is required regarding the use of immunotherapy. The
recent emergence of extensively drug-resistant TB (XDR-TB),
representing MDR-TB with additional bacillary resistance to ﬂuo-
roquinlones and one or more of the second-line injectable drugs –
kanamycin, amikacin and capreomycin, poses a serious challenge
to the global control of TB. Given the escalating size of the
problem of MDR-TB and XDR-TB worldwide, gigantic instillation
of resources is required for control of this formidable challenge,
largely through more accurate and rapid drug susceptibility
testing (especially for rifampicin and ﬂuoroquinolone), regular
drug-resistance surveillance, development of new anti-TB drugs
and other therapeutic modalities, intensive infection control, es-
pecially in HIV care settings, as well as strengthening of currently
functioning DOTS and Drug-Resistance Programmes.
CS13-02 The Anti-TB Treatment for AIDS Patients
Coinfection with TB
Hongzhou Lu*. Division of Infectious Diseases, Fudan University,
Shanghai, China
Objective: In order to take an insight into the treatment of
AIDS and tuberculosis (TB) co-infection, we made a retrospective
study in 9 hospitals in mainland China.
Method: According to the uniﬁed questionary, 241 cases with
such co-infection were enrolled and the data with respect to
therapy and prognosis were analysed.
Result: Pulmonary TB accounted for 59.3%, extra pulmonary TB
for 21.2% and both for 19.5% of the patients. 76.8% of the 241
cases had a CD4 cell count<200 and 58.5%<100. 80.5% of the pa-
tients were treated with anti-tuberculosis medication and 69.7%
with highly active antiretroviral therapy. The regimen of anti-TB
was comprised of two-stage medication. The ﬁrst stage includes
INH, RFP, PZA and EMB while the second stage medication uses
INH and RFP. 203 (84.2%) were still alive and 38 (15.8%) died.
Conclusion: The combination regimen of many anti-TB agents
is potent to curing AIDS/TB co-infection. Generally, 4 anti-TB
agents used in ﬁrst stage for two monthes and 2 drugs used for
anti-TB in second stage for 4 monthes. If the tuberculosis was not
cured by the above regimen, the treatment of 2 agents regimen
should last for 7 monthes. The mortality (15.8%) was high even
with HAART and anti-tuberculosis therapy.
CS13-03 Molecular Diagnosis for Extensively Drug
Resistant Tuberculosis (XDR-TB): Current
Practice and Challenges
Wing Cheong Yam*. Department of Microbiology, Queen Mary
Hospital, The University of Hong Kong, Hong Kong SAR, China
The emergence of extensively drug resistant tuberculosis (XDR-
TB) strains among multi drug resistant tuberculosis (MDR-TB)
patients is widely considered as a serious threat to global TB
control. The diagnosis of XDR-TB is hampered by the absence of
effective and rapid diagnostic techniques for antimycobacterial
susceptibility testing especially in high-burden countries. The
advances in molecular technologies (eg. PCR, reverse hybridiza-
tion and DNA sequencing) represents a rapid diagnostic tool
due to their superior accuracy and cost-effectiveness in the de-
tection of mutations associated with drug resistance. Multiplex
allele-speciﬁc (MAS)-PCRs of mabA (3-ketoacyl reductase) and
katG (catalase-peroxidase) genes identify isoniazid resistance
while rifampin and oﬂoxacin resistance can be detected by PCR-
sequencing of rpoB (RNA polymerase β–subunit) and gyrA (gyrase
A) genes respectively. Direct detection of drug resistance asso-
ciated mutations in mabA, katG, rpoB, and gyrA genes indicate
potential application for rapid diagnosis of XDR-TB, resulting in a
net time gain of 1 to 2-months over conventional antimycobac-
terial susceptibility testing so that early initiation of anti-TB
therapy and management of patients can be initiated.
CS13-04 Antituberculous Therapy: The Impact of
Pharmacokinetic-Pharmacodynamic Parameters
Mamie Hui *. Department of Microbiology, The Chinese
University of Hong Kong, Hong Kong, China
Understanding of pharmacokinetic-pharmacodymic (PK-PD) prin-
ciples has revolutionized our understanding of anti-infective
dosing design. Apart from recognizing the pharmacokinetic prop-
erties (absorption, distribution, metabolism and excretion) of
an antibiotic, the pharmacodymics (such MIC distribution), the
PK-PD interactions such as concentration dependency and time
dependency are all of paramount importance in the design of
appropriate therapy. In the treatment of tuberculosis, as the
treatment duration is usually prolonged, ensuring compliance is
often problematic. Poor compliance will lead to failure of treat-
ment, relapse of disease, and emergence of multi-drug or even
extended-drug resistance. The recognition of speciﬁc property of
a drug, such as persistent effect (also known as post-antibiotic
effect) allows design of single daily dose, or even extended
interval dosing regimen. In vitro models, animal models and clin-
ical trials have ﬂourished in recent years. Rifampicin, isoniazid,
pyrazinamide, ﬂuoroquinolones, oxazolidinone all have individ-
ual PK-PD characteristics in terms of MIC90, Cmax/MIC and AUIC.
These had lead to the development of possible twice weekly or
even weekly regimens, as well as deﬁning mutation selection
window and its protection by the use of appropriate combination
therapy. Improvement in the understanding of these treatment
strategies, will not only maximize the therapeutic efﬁcacy, but
also improve compliance and also long term treatment outcomes.
CS13-05 Identiﬁcation of Latent Tuberculosis Infection by
QuantiFERON-TB GOLD, ELISPOT, and Tuberculin
Skin Test in End-Stage Renal Disease and Healthy
Controls
Ih-Jen Su*. Division of Infectious Diseases, National Health
Research Institutes, Tainan, Taiwan
Identiﬁcation of latent TB infection (LTBI) is an important health
policy issue. In BCG vaccination countries, however, tuberculin
skin test (TST) is difﬁcult to be used as a predictor of TB infec-
tion. Recent application of interferon-γ blood tests has improved
the diagnosis. In this study, we applied and compared these tests
to identify the latent TB infection.
Materials and Methods: This was a prospective, double-
matched, cohort study in which 32 ESRD patients and 32 age-
matched, healthy controls were enrolled. The TST and two new
interferon-γ blood tests, QuantiFERON-TB Gold QFT-G) and T-
SPOT.TB (ELISPOT), were performed. The subjects were followed
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up 2 years for active TB disease. ELISPOT was done in ESRD
patients only.
Results: Compared to the healthy controls, a high prevalence of
LTBI was found in the ESRD patients by TST (62.5%, 95% conﬁ-
dence interval [CI] 43.7–78.9), QFT-G (40.0%, 95% CI 22.7–59.4),
and ELISPOT (46.9%, 95% CI 29.1–65.3). Agreement was moderate
(kappa [κ] = 0.53) for QFT-G and ELISPOT but only slight between
TST and QFT-G (κ = 0.25) and fair between TST and ELISPOT (κ
= 0.32). ESRD (p = 0.03) and diabetes mellitus (p = 0.04) were
signiﬁcant risk factors for QFT-G positivity on the multivariable
analysis. The overall rate of active TB was 1.66 cases per 100
person-years (pys), with the rate higher in patients with ESRD
(3.53 per 100 pys) and those with positive (3.40 per 100 pys)
and indeterminate QFT results (30.16 per 100 pys), although the
difference was not statistically signiﬁcant. Sensitivity, speciﬁcity,
and positive and negative predictive values of QFT-G for active
TB was 100%, 62.1%, 8.3% and 100%.
Conclusion: This pilot study is the ﬁrst to compare QFT-G,
ELISPOT, and TST in ESRD patients on hemodialysis and demon-
strates a high prevalence of LTBI in this population. In our
study, the QFT-G was the more accurate method for identifying
those truly infected with Mycobacterium tuberculosis, even in
BCG-vaccinated individuals.
Concurrent Session 14 – AIDS/STD
CS14-01 Toward Timely HAART: Risks and Beneﬁts
Hongxin Zhao*. AIDS Unit, Beijing Ditan Hospital, Beijing, China
CS14-02 Interaction between Syphilis and HIV Infections
K.M. Kam*. Public Health Laboratory centre, Centre for Health
Protection, Department of Health, Hong Kong
To study the interaction between syphilis and HIV infections
to enhance detection of cases and improve clinical care for
HIV-syphilis coinfected patients.
A review of published literature showed syphilis is associated with
increased risk for HIV sexual transmission and acquisition. HIV
might shift the clinical manifestations of syphilis, rendering le-
sions more apparent, and accelerate the progression of syphilitic
disease. Among HIV-infected persons, atypical and/or multiple
chancres can occur or primary syphilitic lesions might be absent.
Secondary syphilis, particularly acute syphilitic meningitis, can
resemble acute primary HIV infection: constitutional symptoms
with non- focal CNS signs and symptoms and CSF abnormalities
(lymphocytic pleocytosis and mildly elevated CSF protein), are
common. Responses to non-treponemal serologic tests (VDRL,
RPR) can be atypical (higher, lower, delayed) amongst HIV- in-
fected patients with early syphilis. There is, however, little data
that treponemal tests (EIA, FTA, TPPA) perform differently. On
the other hand, it is unknown whether there is difference in prog-
nostic signiﬁcance of CSF abnormalities between HIV- infected
and – noninfected persons. Some recommended CSF examination
for all HIV- infected patients with syphilis regardless of stage, in
particular for RPR ≥ 1:32 or CD4 < 350 per uL. Penicillin remains
treatment of choice for syphilis regardless of HIV status. Most
HIV- infected persons with early syphilis respond to standard
benzathine penicillin although some recommend two additional
weekly benzathine penicillin injections. The beneﬁt of latter
approach remains unknown. Retreatment of early stage syphilis
should be considered when there is sustained 4-fold increase in
serum nontreponemal titres (SNT) after an intial reduction after
treatment, or when there are persistent/recurring clinical signs
and symptoms. Some recommend retreating early syphilis for
those who do not have a 4- fold decrease in SNT at 6- 12 months
after treatment.
Occurrence of syphilis in HIV- infected patient is an indication
of high- risk behaviour and should prompt intensive counseling,
referral for behaviour intervention, screening and treatment for
syphilis as well as for other sexually transmitted diseases.
CS14-03 Emerging of HIV-1 Drug Resistance and Solutions
in Thailand
Somnuek Sungkanuparph*. Division of Infectious Diseases,
Department of Medicine, Faculty of Medicine Ramathibodi
Hospital, Mahidol University, Bangkok, Thailand
Antiretroviral therapy (ART) for HIV-1 infected patients has been
rapidly scaled up worldwide in the last decade. In Thailand, the
national policy of providing free access to ART has been imple-
mented since 2002. Successful outcomes are not always observed
and HIV-1 drug resistance is a major cause of treatment failure.
The emergence and transmission of drug-resistant HIV-1 infection
inevitably follows the increasing use of ART, which reduces the
efﬁcacy of the ﬁrst-line ART. This suggests that scaling up of
access to ART in Thailand is becoming vulnerable to be at risk of
the HIV-1 drug resistance problem. Both primary and secondary
drug resistance have been observed. In Thailand, a recent pub-
lished data has shown 2% of HIV-1 drug resistance among persons
with recent infection, which increased from 0% in 2003 to 5.2% in
2006. All seven patients with viral resistance had sexual partner
with low adherence and treatment failure with NNRTI-based reg-
imen. This suggests that HIV-1 drug resistance was transmitted
among couples. Intervention of prevention program, i.e. 100%
condom campaign, needs to be re-strengthened and emphasized.
The prevalence of primary resistance depends on the character-
istics of study population especially duration of HIV-1 infection.
Another study had found baseline antiretroviral drug resistance
mutations in 4% of Thai HIV-1 infected patients with unknown
duration of HIV-1 infection. Nevertheless, data of primary HIV-1
drug resistance in Thailand is still limited. A study to determine
the prevalence and risk factors of primary HIV-1 drug resistance,
using surveillance drug resistance mutations recommended for
surveillance of transmitted HIV-1 drug resistance by WHO in
2009, is ongoing in Thailand. To date, the implementation HIV-1
resistance testing for treatment naïve patients in Thailand is not
currently feasible because of the high cost and cost-effectiveness
issue. However, selected group of patients with high risk of pri-
mary HIV-1 drug resistance should be considered.
Secondary HIV-1 drug resistance has become common in Thailand
after rapid scaling up of ART. Resistance mutations to NRTIs
and NNRTIs are the most common form, reﬂecting local pre-
scription patterns. Thai ART guidelines have recommended a
ﬁxed-dose combination of stavudine/zidovudine, lamivudine and
nevirapine (d4T/3TC/NVP or AZT/3TC/NVP) as preferred initial
regimens. A prospective cohort study in patients who were ini-
tiated d4T/3TC/NVP has shown that 9.3% of patients developed
HIV-1 drug resistance within 3 years. Another study of geno-
typic resistance testing conducted among HIV-1 infected patients
who experienced treatment failure with their ﬁrst antiretrovi-
ral regimen of d4T/3TC/NVP during 2003-2005 in Thailand has
demonstrated that late detection of virological failure is asso-
ciated with extensive HIV-1 drug resistance and limited options
for a second-line regimen. In resource-limited settings where
availability of antiretroviral agents is limited, strategies for pre-
vention of HIV-1 resistance are crucial. The adherence to ART
is the key of successful treatment. Early detection of virologi-
cal failure with regular monitoring of treatment responses may
provide more options and better treatment outcomes.
